Vision Statement:

To advance the science of neurotherapeutics, and to improve and accelerate the development of new treatments.

www.asent.org
# ASENT

## Corporate Partners

List as of March 3, 2016

<table>
<thead>
<tr>
<th>Level</th>
<th>Amount Range</th>
<th>Partners</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diamond</td>
<td>$25,000 - $49,999</td>
<td>Biogen</td>
</tr>
</tbody>
</table>
| Platinum    | $10,000 - $24,999    | Acorda Therapeutics, Inc.  
Lundbeck Pharmaceuticals Services, LLC |
| Gold        | $7,500 - $9,999      | Allergan, Inc.  
Cyberonics  
Upsher-Smith Laboratories, Inc. |
| Silver      | $5,000 - $7,499      | Adamas Pharmaceuticals  
Avanir Pharmaceuticals, Inc.  
Supernus Pharmaceuticals  
Valeant Pharmaceuticals North America LLC |
| Bronze      | $2,500 - $4,999      | Biocodex Pharmaceuticals  
Chase Pharmaceuticals  
Eisai  
KM Pharmaceutical Consulting, LLC  
NeuroPace, Inc.  
Nevro Corp  
Sughrue Mion, PLLC |
| Supporter   | $1,000 - $2,499      | AbbVie, Inc.  
Amarex  
Cognitive Research Corp.  
GTP Pharmaceuticals  
GW Pharmaceuticals  
Riverside Pharmaceuticals |

[www.asent.org](http://www.asent.org)

18th Annual Meeting
# Table of Contents

- Meeting Room Layout ............................................................ 2
- Program Schedule .............................................................. 3-8
- Annual Business Meeting ...................................................... 10
- Support Recognition ........................................................ 12-20
- Pipeline Presentations ..................................................... 21-23
- Pipeline Posters .............................................................. 24-27
- 18th Annual Meeting Program Committee ............................. 28
- ASENT Board of Directors .................................................... 29
- Schedule-At-A-Glance ....................................................... Back Cover
American Society for Experimental NeuroTherapeutics

Floor Plan

Main Level

- Salon A
- Salon B
- Salon C
- Salon D
- Salon E
- Salon F
- Salon G
- Salon H

PRE-FUNCTION AREA

Registration & Breaks

Escalator Down

Meals

Posters & Reception

To Hotel

18th Annual Meeting
# Program Schedule

**THURSDAY, MARCH 17, 2016**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 8:30 a.m. – 9:00 a.m. | Continental Breakfast  
*Grand Ballroom - Salon A-C Foyer* |
| 9:00 a.m. – 9:30 a.m. | Presidential Welcome  
Howard Federoff, MD, PhD, President (ASENT)  
University of California, Irvine  
**Funding Agencies: Facilitating Neurotherapeutics**  
Amir Tamiz, PhD  
NINDS  
Phil Skolnick, PhD, DSc (hon.)  
NIDA |
| 9:30 a.m. – 12:30 p.m. | First Symposium  
**Psychedelic Agents as Leads for CNS Drug Discovery**  
Chair: Martha Morrell, MD  
NeuroPace  
- *Neuroimaging Research with Psychedelic Drugs*  
  David Nutt, DM FRCP FRCPsych FMedSci  
  Imperial College London  
- *Ketamine and Other Glutamatergic Antagonists for Depression*  
  Carlos A. Zarate, Jr. MD  
  National Institute of Mental Health  
- *Muscarinic Agonists and Antagonists for Psychosis*  
  Christian C. Felder, PhD  
  Eli Lilly  
- *Therapeutic Applications of Psilocybin*  
  Paul Hutson, PharmD, BCOP  
  University of Wisconsin  
- *Regulatory Aspects of Drug Development*  
  Mitchell Mathis, MD  
  FDA–Drug Evaluation  
- *Perspectives of Patient Advocacy Groups*  
  Philip Gattone, MEd  
  EFA |
| 12:30 p.m. – 2:00 p.m. | Lunch  
*Recognition of ASENT Sponsors*  
Kathleen Clarence-Smith, MD, PhD  
**ASENT Business Meeting**  
Howard Federoff, MD, PhD, President (ASENT) |
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 2:00 p.m. – 5:00 p.m. | **Second Symposium**  
**Neurotherapeutic Devices**  
Co-Chairs: Victor Krauthamer, PhD  
FDA  
Martha Morrell, MD  
NeuroPace  

- **History and Introduction to the Current State of the Field**  
  Victor Krauthamer, PhD  
  FDA  
  Martha Morrell, MD  
  NeuroPace  

**Neuromodulation Therapies**  
- **Cellular and Network Mechanisms of the Response to Electrical Stimulation**  
  Eugene Civillico, PhD  
  FDA/CDRH/OSEL  

- **Spinal Cord and Peripheral Nerve Stimulation**  
  Joshua Prager, MD, MS  
  UCLA  

- **Vagus Nerve and Brain Stimulation**  
  Robert Gross, MD, PhD  
  Emory University  

**Spurring and Supporting the Development of Neuromodulation Therapies**  
- **Navigating the Regulatory Landscape for Neurological and Physical Medicine Devices**  
  Carlos Pena, PhD, MS  
  FDA/CDRH  

- **NIH Support for Initiatives in Neuromodulation**  
  Felipe Aguel, PhD  
  NINDS/NIH  

- **Neurotherapeutic Devices: Obstacles and Opportunities**  
  Panel Discussion - Frank Fischer, MS;  
  Jeff Nye, MD, PhD; Victor Krauthamer, PhD;  
  Joshua Prager, MD, MS; Carlos Pena, PhD, MS;  
  Robert Gross, MD, PhD; Felipe Aguel, PhD;  
  Eugene Civillico, PhD  

**Break**  
3:40 p.m. – 3:55 p.m.  
Grand Ballroom - Salon A-C Foyer
**American Society for Experimental NeuroTherapeutics**

**Program Schedule (Continued)**

**THURSDAY, MARCH 17, 2016**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:00 p.m. – 6:00 p.m.</td>
<td>Reception</td>
<td>Grand Ballroom - Salon A-C Foyer</td>
</tr>
<tr>
<td>6:00 p.m. – 8:30 p.m.</td>
<td>Dinner</td>
<td>Grand Ballroom - Salon D</td>
</tr>
</tbody>
</table>

**Dinner**
Co-Chairs: Martha Morrell, MD
NeuroPace
Howard Federoff, MD, PhD
University of California – Irvine

**Careers in Neurotherapeutics**

**Welcome and Introduction**
Martha Morrell, MD
NeuroPace

**Careers in Academic Clinical Neuroscience**
Howard Federoff, MD, PhD
University of California – Irvine

**Careers in Academic Basic Neuroscience**
Michael Rogowski, MD, PhD
University of California – Davis

**Careers at NIH**
Felipe Aguel, PhD
NINDS/ NIH

**Careers at FDA**
Carlos Pena, PhD, MS
FDA/ CDRH

**Careers in Pharma**
Gilmore O’Neill, MD, MRCP, MMedSc
Biogen

**Careers in Medical Devices**
Frank Fischer, MS
NeuroPace

**Careers in Industry: Pharma, R&D, Business Partnering and Start-Up Companies**
Jeffrey Nye, MD, PhD
Johnson & Johnson

**Panel Discussion – All speakers**

**Round Table Discussions**
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m. – 8:30 a.m.</td>
<td>Continental Breakfast</td>
</tr>
<tr>
<td></td>
<td>Grand Ballroom - Salon A-C Foyer</td>
</tr>
<tr>
<td>8:30 a.m. – 9:30 a.m.</td>
<td>Breakfast Lecture</td>
</tr>
<tr>
<td></td>
<td>Gene-based Therapeutics for Parkinson’s Disease: Innovations and Clinical Success</td>
</tr>
<tr>
<td></td>
<td>Chair: Tony Altar, PhD</td>
</tr>
<tr>
<td></td>
<td>AssureRx Health;</td>
</tr>
<tr>
<td></td>
<td>Krys Bankiewicz, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>University of California – San Francisco</td>
</tr>
<tr>
<td>9:30 a.m. – 10:00 a.m.</td>
<td>Break/Networking</td>
</tr>
<tr>
<td></td>
<td>Grand Ballroom - Salon A-C Foyer</td>
</tr>
<tr>
<td>10:00 a.m. – 12:00 p.m.</td>
<td>Pipeline Oral Morning Session</td>
</tr>
<tr>
<td></td>
<td>Co-Chairs: Kathleen Clarence-Smith, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>KM Pharmaceuticals Consulting, LLC</td>
</tr>
<tr>
<td></td>
<td>Roger Porter, MD</td>
</tr>
<tr>
<td></td>
<td>Maral Mouradian, MD</td>
</tr>
<tr>
<td></td>
<td>MentiNova, Inc</td>
</tr>
<tr>
<td></td>
<td>Amir Tamiz, PhD</td>
</tr>
<tr>
<td></td>
<td>NIH</td>
</tr>
<tr>
<td>12:00 p.m. – 1:30 p.m.</td>
<td>Lunch</td>
</tr>
<tr>
<td></td>
<td>Grand Ballroom - Salon D</td>
</tr>
<tr>
<td>1:30 p.m. – 3:45 p.m.</td>
<td>Pipeline Oral Afternoon Session</td>
</tr>
<tr>
<td></td>
<td>Co-Chairs: Kathleen Clarence-Smith, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>Roger Porter, MD</td>
</tr>
<tr>
<td></td>
<td>Maral Mouradian, MD</td>
</tr>
<tr>
<td></td>
<td>Amir Tamiz, PhD</td>
</tr>
<tr>
<td>3:45 p.m. – 6:30 p.m.</td>
<td>All Pipeline Presenters: Posters &amp; Reception</td>
</tr>
<tr>
<td></td>
<td>Chair: Kathleen Clarence-Smith, MD, PhD</td>
</tr>
<tr>
<td>6:30 p.m. – 8:30 p.m.</td>
<td>Dinner Symposium</td>
</tr>
<tr>
<td></td>
<td>Co-Chairs: Kathleen Clarence-Smith, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>Mitchell Brin, MD</td>
</tr>
<tr>
<td></td>
<td>Allergan</td>
</tr>
<tr>
<td></td>
<td>Marc Walton, MD</td>
</tr>
<tr>
<td></td>
<td>Janssen Research &amp; Development, LLC</td>
</tr>
<tr>
<td></td>
<td>Food for Thought: “Nutraceuticals,” Their Impact on Brain Health</td>
</tr>
<tr>
<td></td>
<td>• Regulation of Dietary Supplements and Medical Foods</td>
</tr>
<tr>
<td></td>
<td>Ricardo Carvajal, JD, MS</td>
</tr>
<tr>
<td></td>
<td>Hyman, Phelps &amp; McNamara</td>
</tr>
</tbody>
</table>
### FRIDAY, MARCH 18, 2016

#### Dinner Symposium continued

- **Nutrients That Modulate Synapse Formation**  
  Richard Wurtman, MD  
  MIT

- **Nutrition and Alzheimer's Disease**  
  Edward Mascioli, MD  
  SV Life Sciences

  Panel Discussion - Ricardo Carvajal, JD, MS; Richard Wurtman, MD; Edward Mascioli, MD

### SATURDAY, MARCH 19, 2016

#### 8:00 a.m. – 9:00 a.m. Continental Breakfast

**Grand Ballroom - Salon A-C Foyer**

#### 9:00 a.m. – 12:00 p.m. Third Symposium

**Grand Ballroom - Salon A-C**

**Biosimilars: Development and Regulatory Challenges**

Co-Chairs: Thomas Chase, MD; Chase Pharmceuticals;  
Marc Walton, MD, PhD; Janssen Research & Development, LLC; Mitchell Brin, MD; Allergan;

- **Overview: Bio-Originals and Biosimilars**  
  Jay P. Siegel, MD  
  Johnson & Johnson

- **Global Biosimilar Development: Reflections on 15 Years’ Experience of Practical Challenges and Opportunities**  
  Crawford Brown, PhD  
  Allergan Biologics, Ltd.

- **Developing World Class Biosimilars**  
  Steven Lehrer, MBA  
  Cipla Biotec, Cipla

- **The Manufacturing of Therapeutic Proteins**  
  Kathleen Clouse, PhD  
  FDA

- **An Update on Biosimilar Regulation in Japan**  
  Ken Sakushima, MD, MPH, PhD  
  Pharmaceuticals and Medical Devices Agency (PMDA)

- **Biosimilars: The European Dimension**  
  Sir Michael Rawlins, MD  
  Medicines and Healthcare Products Regulatory Agency (MHRA)
### Fourth Symposium

**Lifestyle: An Integral Component of Brain Health Examples from Multiple Sclerosis and Parkinson’s Disease**

Co-Chairs: Robert Hamill, MD  
University of Vermont, College of Medicine;  
Amy Chappell, MD  
Convergence Pharmaceuticals;  
Robin Elliott, MA  
Parkinson’s Disease Foundation;  
Richard Rudick, MD  
Biogen Idec, Inc

- **Overview of Wellness and Preventative Care on Management of Neurodegenerative Diseases Using MS as the Prototype**  
  Kathy Costello, MS, ANP-BC  
  National MS Society; Johns Hopkins University

- **Science Related to Forced Exercise in Parkinson’s Disease - Implications for Understanding and Treating Neurodegenerative Disease**  
  Jay Alberts, PhD  
  Cleveland Clinic

- **Science Related to Exercise in Multiple Sclerosis - Implications for Understanding and Treating Neurodegenerative Disease**  
  Robert Motl, PhD  
  University of Illinois

- **Effects of Environmental Factors and Health Behavior on Multiple Sclerosis**  
  Kassandra Munger, ScD  
  Harvard T.H. Chan School of Public Health

**Group Discussion**
Spring Membership Meeting

Thursday, March 17, 2016

Bethesda Marriott Hotel and Conference Center
1:00-2:30 pm | Brookside Room

The American Brain Coalition is excited to announce Dr. Walter Koroshetz, Director of the National Institute of Neurological Disorders & Stroke to participate as a special guest at the American Brain Coalition Spring Membership Meeting.
Annual Business Meeting

Thursday, March 17, 2016
Bethesda North Marriott Hotel & Conference Center
Grand Ballroom - Salon D
1:15 p.m. - 1:45 p.m.

I. Call to Order
II. Support Recognition
III. Financial Report
III. 2016 Executive and Board Member Recognition and Installation
IV. Neurotherapeutics® Journal Report
V. Membership Report
VI. Old Business
VII. New Business
VIII. Adjournment
Join Us...

for the ASENT 19th Annual Meeting

March 14-19, 2017

Hilton Washington-DC/Rockville Hotel & Executive Meeting Center
1750 Rockville Pike
Rockville, MD 20852
Thank you for supporting
Diamond Level Corporate Partner

Biogen™
Thank you for supporting ASENT

Platinum Level
Corporate Partner

ACORDA
THERAPEUTICS
Thank you for supporting ASENT

Platinum Level
Corporate Partner
Thank you for supporting ASENT

Gold Level Corporate Partner

Allergan

Gold Level Corporate Partner

Cyberonics

Gold Level Corporate Partner

UPSHER-SMITH

Partners in Health Since 1919
Thank you for supporting ASENT

Silver Level
Corporate Partner

ADAMAS™

Silver Level
Corporate Partner

AVANIR®

Silver Level
Corporate Partner

Supernus® Pharmaceuticals
Thank you for supporting ASENT

Silver Level
Corporate Partner

Bronze Level
Corporate Partner

Bronze Level
Corporate Partner

Bronze Level
Corporate Partner

Bronze Level
Corporate Partner
Thank you for supporting ASENT

Bronze Level Corporate Partner

NEUROPACE

Bronze Level Corporate Partner

nevro®

Bronze Level Corporate Partner

Sughrue

SUGHRUE MION, PLLC
INTELLECTUAL PROPERTY LAW
Thank you for supporting ASENT

Supporter Level Corporate Partner

AbbVie

Supporter Level Corporate Partner

Cognitive Research Corporation

Supporter Level Corporate Partner

GTP Pharmaceuticals

Supporter Level Corporate Partner

GW Pharmaceuticals

Supporter Level Corporate Partner

Riverside Pharmaceuticals
Pipeline Presentations

**Morning Session**

**Introduction**
*Kathleen Clarence-Smith, MD, PhD; Roger Porter, MD*

**Genetic Switch of E1A for Oncolytic Adenoviral Transformation in Carrier Mesenchymal Stem in Response to Hypoxia**
*Hiroshi Nakashima, PhD; Tran Nguyen; Imran Shaik, MD; J. Bradley Elder, MD; E. Antonio Chiocca, MD, PhD*

**Can Neurostimulation Replace Narcotics?**
*Joseph W. Boggs, PhD*

**Biopolymer Device to Stop Bleeding During Brain Surgery**
*Richard Russo, MBA*

**Pharmacogenomics of Antidepressant Medication Selection**
*Tony Altar, PhD*

**The Discovery and Development of EMB-001 for the Treatment of Substance Use Disorders**
*Michael Detke, MD, PhD*

**NP10679: A Selective pH Sensitive GluN2B Inhibitor to Improve Outcomes Post Subarachnoid Hemorrhage by Preventing Ischemic Neuronal Damage**
*Robert Zaczek, PhD; S.J. Myers; D T. Laskowitz; K. Ruppa; D.S. Menaldino; P. Lyuboslavsky; G.W. Koszalka, PhD*

**Novel Ways to Enhance CNS Dopamine Concentrations**
*Peter LeWitt, MD*

**Ecopipam for the Treatment of Tourette’s Syndrome**
*Richard E. Chipkin, PhD*

**Clinical Development of Glanaxolene as an Intravenous (IV) Formulation**
*Jaakko Lappalainen, MD, PhD; Michael Saporito, PhD*

**NINDS Programs for Translational Research: Lessons Learned for CNS Preclinical Development**
*Amir Tamiz, PhD*
Afternoon Session

Propofol Hemisuccinate: An Inhaled Treatment for Epilepsy and Migraine
**Michael Rogawski, MD, PhD**

Nalbuphine Efficacy for L-Dopa Induced Dyskinesia in Parkinson's Disease
**M. Maral Mouradian, MD**

PGC-1a: A New Therapeutic Target for Neurodegenerative Disorders
**Howard Federoff, MD, PhD**

Isoform Selective Kv11.1 Inhibitors for Treatment of Psychiatric Conditions
**James Barrow, PhD**

Iduronidase Replacement Therapy of the Brain in Hurler Syndrome
**Ruben J. Boado, PhD**

Dendrimer Delivery of N-Acetylcycteine (D-NAC) Provides Delayed Protection For Perinatal Brain Injury
**Michael Johnston, MD; Ali Fatemi, MD; Mary Ann Wilson, PhD; Sujatha Kannan, MD, PhD; Kannan Rangaramanujam, MS, PhD; Christina Mertz, Manoj Mishra**

Synthetic Transient Receptor Potential (TRP) Activators Demonstrate Efficacy in Preventing Human Muscle Cramping: Potential New Drug Treatment for Muscle Cramps and Spasticity
**Laura Rosen, MD, PhD; Robin Sutherland, BS, OT/L; Eric O Solberg, BS; Angela Tornblom, BS; Brooke Hegarty, MSHS; Jian Liu, PhD; Glenn Short, PhD; Christoph Westphal, MD, PhD; Jennifer Cermak, PhD**

Small Molecule Drugs for Treatment of Dry Age-related Macular Degeneration
**Konstantin Petrukhin, PhD**

Developing Clinical-Grade Cell Therapy for Spinal Cord Regeneration
**Hatem Sabaawy, MD, PhD**

The Anticonvulsant and Neuroprotective Efficacy of GluK1 Kainate Receptor Antagonists: A Novel Therapeutic Against Nerve Agent-induced Seizures and Brain Damage
**Maria Braga, DDS, PhD**
Afternoon Session cont.

Identification and Characterization of a Novel and Highly Selective D2 Dopamine Receptor Antagonist

*David Sibley, PhD*

Concluding Remarks

*Maral Mouradian, MD, Amir Tamiz, PhD*

Notes
1. Genetic Switch of E1A for Oncolytic Adenoviral Transformation in Carrier Mesenchymal Stem in Response to Hypoxia
   Hiroshi Nakashima, PhD; Tran Nguyen; Imran Shaik, MD; J. Bradley Elder, MD; E. Antonio Chiocca, MD, PhD

2. Can Neurostimulation Replace Narcotics?
   Joseph W. Boggs, PhD

3. Biopolymer Device to Stop Bleeding During Brain Surgery
   Richard Russo, MBA

4. Pharmacogenomics of Antidepressant Medication Selection
   Tony Altar, PhD

5. The Discovery and Development of EMB-001 for the Treatment of Substance Use Disorders
   Michael Detke, MD, PhD

6. NP10679: A Selective pH Sensitive GluN2B Inhibitor to Improve Outcomes Post Subarachnoid Hemorrhage by Preventing Ischemic Neuronal Damage
   Robert Zaczek, PhD; S.J. Myers; D.T. Laskowitz; K. Ruppa; D.S. Menaldino; P. Lyuboslavsky; G.W. Koszalka, PhD

7. Novel Ways to Enhance CNS Dopamine Concentrations
   Peter LeWitt, MD

8. Ecopipam for the Treatment of Tourette’s Syndrome
   Richard E. Chipkin, PhD

9. Clinical Development of Glanaxolene as an Intravenous (IV) Formulation
   Jaakko Lappalainen, MD, PhD; Michael Saporito, PhD

10. NINDS Programs for Translational Research: Lessons Learned for CNS Preclinical Development
    Amir Tamiz, PhD

11. Propofol Hemisuccinate: An Inhaled Treatment for Epilepsy and Migraine
    Michael Rogawski, MD, PhD

12. Nalbuphine Efficacy for L-Dopa Induced Dyskinesia in Parkinson’s Disease
    M. Maral Mouradian, MD

13. PGC-1α: A New Therapeutic Target for Neurodegenerative Disorders
    Howard Federoff, MD, PhD
14. Isoform Selective Kv11.1 Inhibitors for Treatment of Psychiatric Conditions
   *James Barrow, PhD*

15. Iduronidase Replacement Therapy of the Brain in Hurler Syndrome
   *Ruben J. Boado, PhD*

16. Dendrimer Delivery of N-Acetylcysteine (D-NAC) Provides Delayed Protection For Perinatal Brain Injury
   *Michael Johnston, MD; Ali Fatemi, MD; Mary Ann Wilson, PhD; Sujatha Kannan, MD, PhD; Kannan Rangaramanujam, MS, PhD; Christina Mertz, Manoj Mishra*

17. Synthetic Transient Receptor Potential (TRP) Activators Demonstrate Efficacy in Preventing Human Muscle Cramping: Potential New Drug Treatment for Muscle Cramps and Spasticity
   *Laura Rosen, MD, PhD; Robin Sutherland, BS, OT/L; Eric O Solberg, BS; Angela Tornblom, BS; Brooke Hegarty, MSHS; Jian Liu, PhD; Glenn Short, PhD; Christoph Westphal, MD, PhD and Jennifer Cermak, PhD*

18. Small Molecule Drugs for Treatment of Dry Age-related Macular Degeneration
   *Konstantin Petrukhin, PhD*

19. Developing Clinical-Grade Cell Therapy for Spinal Cord Regeneration
   *Hatem Sabaawy, MD, PhD*

20. The Anticonvulsant and Neuroprotective Efficacy of GluK1 Kainate Receptor Antagonists: A Novel Therapeutic Against Nerve Agent-induced Seizures and Brain Damage
   *Maria Braga, DDS, PhD*

21. Protection of Scutellarin Against Oxygen Glucose Deprivation/Reperfusion Induced Astrocytes Injury by Inhibiting NADPH Oxidase In Vitro
   *Yan Li, PhD; Guangshun Sun; Shu Liu; Jingbo Sun*

22. Cuprizone Mouse Model of Demyelination: Environmental Enhancement Reverses Cognitive Deficits
   *Amal Almahroos, BSc; Zahra S.Ali Almosawi; Reem Merza; Hawra Alalwan*
Pipeline Posters

23. **Effects of Induced Depression on the Animal Model of Multiple Sclerosis: An Overlooked Disability**  
*Zahra Sayed Almosawi, BSc; Amal Almahroos; Hawra Alalwan; Reem Merza*

25. **Effect of Rhythmic Auditory Stimulation On Gait In Patients With Stroke**  
*Mohamed Ahmed Fouad, MD*

26. **Multicenter Randomized Controlled Pivotal Trial Comparing 10 kHz and Traditional Spinal Cord Stimulation: 24-month Results**  
*Leonardo Kapural, MD, PhD; Cong Yu, MD; Matthew W. Doust, MD; Bradford E. Gliner, MS*

27. **Long-term Outcomes of Predominant Leg Pain and Predominant Back Pain Cohorts from a Multicentre Randomized Controlled Pivotal Trial (SENZA-RCT) Comparing 10 kHz High Frequency and Traditional Low Frequency Spinal Cord Stimulation**  
*B. Todd Sitzman, MD, MPH; Leonardo Kapural; Cong Yu, MD; Matthew W. Doust, MD*

28. **The effects of various angiotensin receptor blockers on experimental autoimmune neuritis in rats**  
*Toshiki Fujioka, MD*

29. **Synthetic Transient Receptor Potential (TRP) Ion Channel Activators Demonstrate Efficacy in Preventing Human Muscle Cramping: Potential New Drug Treatment for Muscle Cramps and Spasticity**  
*Laura B. Rosen, MD, PhD; Robin Sutherland; Eric Solberg; Angela Tornblom*

30. **The Discovery and Development of EMB-001 for the Treatment of Substance Use Disorders**  
*Michael Detke, MD, PhD; Carol Gloff; Gary Connor; Julie Straub*

31. **Clinical relative bioavailability of AZD3293, a novel beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor: assessment of tablet formulation versus oral solution and GI effect on pharmacokinetics**  
*Naidong Ye, PhD; Pankaj Daga; Scott A. Monk; David M. Bender*
32. The Benefits of Resveratrol in Parkinson’s Disease: A Five-year Case Study
   Elizabeth K. Barber, PhD; Barber Innovations LLC

33. Identification and Characterization of a Novel and Highly Selective D2 Dopamine Receptor Antagonist
   David Sibley, PhD

Notes
<table>
<thead>
<tr>
<th>Name</th>
<th>Title/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>C. Anthony Altar, PhD, Chair</td>
<td>AssureRx Health, Inc.</td>
</tr>
<tr>
<td>Bennett Lavenstein, MD, Co-Chair</td>
<td>Children’s Hospital Medical Center</td>
</tr>
<tr>
<td>Mitchell Brin, MD</td>
<td>Allergan, Inc.</td>
</tr>
<tr>
<td>Jessee M. Cedarbaum, MD</td>
<td></td>
</tr>
<tr>
<td>Amy S. Chappell, MD</td>
<td>Convergence Pharmaceuticals, Ltd</td>
</tr>
<tr>
<td>Kathleen E. Clarence-Smith, MD, PhD</td>
<td>KM Pharmaceuticals Consulting, LLC</td>
</tr>
<tr>
<td>Robin A. Elliott, MA</td>
<td>Parkinson’s Disease Foundation &amp; World Parkinson Congress</td>
</tr>
<tr>
<td>Howard J. Federoff, MD, PhD</td>
<td>University of California – Irvine</td>
</tr>
<tr>
<td>Victor Krauthamer, PhD</td>
<td>FDA Office of Device Evaluation</td>
</tr>
<tr>
<td>Petra Kaufman</td>
<td>NCATS</td>
</tr>
<tr>
<td>Robert W. Hamill, MD</td>
<td>University of Vermont College of Medicine</td>
</tr>
<tr>
<td>Martha Morrell, MD</td>
<td>NeuroPace, Inc.</td>
</tr>
<tr>
<td>Jill G.C. Rasmussen</td>
<td>Psi-Napse</td>
</tr>
<tr>
<td>Marc Walton, MD, PhD</td>
<td>Janssen Research and Development</td>
</tr>
</tbody>
</table>
OFFICERS
PRESIDENT (2014-2016)
Howard Federoff, MD, PhD
University of California – Irvine

PRESIDENT-ELECT (2014-2016)
Martha Morrell, MD
NeuroPace, Inc.

IMMEDIATE PAST PRESIDENT
(2012-2014)
Michael Rogawski, MD, PhD
University of California, Davis

SECRETARY
Robin Elliott, MA
Parkinson’s Disease Foundation & World Parkinson Congress

TREASURER
Robert W. Hamill, MD
University of Vermont College of Medicine, Department of Neurological Sciences

BOARD OF DIRECTORS
2013 – 2016
Timothy Coetzee, PhD
National Multiple Sclerosis Society

O’Neill D’Cruz, MD, MBA, FAAN

Lynn Kramer, MD
Eisai, Inc.

Bernard Ravina, MD
Biogen Idec, Inc.

BOARD OF DIRECTORS
2014-2017
Merit Cudkowicz, MD, MSc
Massachusetts General Hospital

Russell Katz, M.D.

Victor Krauthamer, PhD
FDA Office of Device Evaluation

Richard Rudick, MD
Biogen

BOARD OF DIRECTORS
2015-2018
Amy S. Chappell, MD
Convergence Pharmaceuticals, Ltd.

Bennett L. Lavenstein, MD
Children’s Hospital Medical Center

EX-OFFICIO BOARD MEMBERS
Development Committee Chair
Kathleen Clarence-Smith, MD, PhD
KM Pharmaceuticals Consulting, LLC

Neurotherapeutics®
Editor-in-Chief
M. Maral Mouradian, MD
Rutgers University

Program Committee Co-Chairs
Bennett Lavenstein, MD
Children’s Hospital Medical Center

C. Anthony Altar, PhD
AssureRx Health Inc.

NIH Blueprint Course Liaison
Barbara Slusher, PhD, MAS
John Hopkins Brain Science Institute
**Schedule-At-A-Glance**

**Wednesday, March 16, 2016**
5:00 p.m. – 7:00 p.m. Registration  
Grand Ballroom Salon A-C Foyer

**Thursday, March 17, 2016**
7:30 a.m. – 6:30 p.m. Registration  
Grand Ballroom, Salon A-C Foyer
8:30 a.m. – 9:00 a.m. Continental Breakfast  
Grand Ballroom, Salon A-C Foyer
9:00 a.m. – 9:30 a.m. Welcome: Funding Agencies  
Grand Ballroom, Salon A-C
9:00 a.m. – 12:30 p.m. General Session: Psychedelic Agents as Leads for CNS Drug Discovery  
Grand Ballroom, Salon A-C
12:30 p.m. – 2:00 p.m. Lunch / ASENT Business Meeting  
Grand Ballroom, Salon D
2:00 p.m. – 5:00 p.m. General Session: Neurotherapeutic Devices  
Grand Ballroom, Salon A-C
5:00 p.m. – 6:00 p.m. Reception  
Grand Ballroom, Salon A-C Foyer
6:00 p.m. – 8:30 p.m. Dinner: Careers in Neurotherapeutics  
Grand Ballroom – Salon D

**FRIDAY, MARCH 18, 2016**
7:30 a.m. – 6:30 p.m. Registration  
Grand Ballroom, Salon A-C Foyer
8:00 a.m. – 8:30 a.m. Continental Breakfast  
Grand Ballroom, Salon A-C Foyer
8:30 a.m. – 9:30 a.m. Breakfast Lecture: Gene-based Therapeutics for Parkinson’s Disease: Innovations and Clinical Success  
Grand Ballroom, Salon A-C
10:00 a.m. – 12:00 p.m. Pipeline Session  
Grand Ballroom, Salon A-C
12:00 p.m. – 1:30 p.m. Lunch  
Grand Ballroom, Salon D
1:30 p.m. – 3:45 p.m. Pipeline Session  
Grand Ballroom, Salon A-C
3:45 p.m. – 6:30 p.m. Posters & Reception  
Grand Ballroom, Salon F&G
6:30 p.m. – 8:30 p.m. Dinner: Food for Thought: “Nutraceuticals,” Their Impact on Brain Health  
Grand Ballroom, Salon D

**SATURDAY, MARCH 19, 2016**
8:00 a.m. – 4:00 p.m. Registration  
Grand Ballroom, Salon A-C Foyer
8:00 a.m. – 9:00 a.m. Continental Breakfast  
Grand Ballroom, Salon A-C Foyer
9:00 a.m. – 12:00 p.m. General Session: Biosimilars: Development and Regulatory Challenges  
Grand Ballroom, Salon A-C
12:00 p.m. – 1:00 p.m. Lunch  
Grand Ballroom, Salon D
1:00 p.m. – 4:30 p.m. General Session: Lifestyle: An Integral Component of Brain Health Examples from Multiple Sclerosis and Parkinson Disease  
Grand Ballroom, Salon A-C

*All events take place at the Bethesda North Marriott Hotel & Conference Center*

**ASENT**  |  342 North Main Street, Suite 301  |  West Hartford, CT 06117-2507  
**Phone:** 860-586-7570  |  **Fax:** 860-586-7550  |  **Email:** info@asent.org  |  **www.asent.org**